Colorectal cancer detection kit Genecan®

for BRAF mutationsfor KRAS mutationsfor NRAS mutations

The risk of colorectal cancer is closely related to lifestyle. Increased intake of food from animals and overweight due to sedentary are associated with the risk of colorectal cancer. Other risk factors include alcohol intake, smoking, eating red or processed meat. Proper supplementation of calcium, cereals, fiber and dairy products can reduce its risk. In recent years, with the improvement of social and economic level. The overall incidence rate and mortality rate of colorectal cancer in China showed a significant upward trend, and the proportion of colorectal cancer increased year by year. Application of molecular detection in colorectal cancer: With the development of deep research and detection level of tumor related molecular markers such as Ras, BRAF, mismatch repair / microsatellite instability (MMR / MSI), reasonable detection technology and application have become an important part of clinical practice. APPLICABLE PEOPLE 1. Recommendation on stage I ~ III colorectal cancer: before adjuvant treatment decision of colorectal cancer. 2. Recommendation on stage IV colorectal cancer: before the decision of first-line treatment plan. 3. Formulate diagnosis and treatment strategies and schemes according to different molecular characteristics of colorectal cancer. DETECTION SIGNIFICANCE 1. It contains RAS, BRAF and HER2 genes to predict the response to anti-EGFR monoclonal antibody, BRAF/MEK inhibitor or anti-HER2 therapy. 2. It contains marker MSI site of immunosuppressant Pembrolizumab. 3. It contains UGT1A1 and DYPD genes related to chemotherapy, which can adjust the medication of irinotecan, fluorouracil, capecitabine and Ftorafur.